CH679010A5 - - Google Patents
Download PDFInfo
- Publication number
- CH679010A5 CH679010A5 CH1787/89A CH178789A CH679010A5 CH 679010 A5 CH679010 A5 CH 679010A5 CH 1787/89 A CH1787/89 A CH 1787/89A CH 178789 A CH178789 A CH 178789A CH 679010 A5 CH679010 A5 CH 679010A5
- Authority
- CH
- Switzerland
- Prior art keywords
- hard gelatin
- gelatin capsules
- nifedipine
- water
- fatty acid
- Prior art date
Links
- 239000002775 capsule Substances 0.000 claims description 47
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 40
- 229960001597 nifedipine Drugs 0.000 claims description 35
- 239000007903 gelatin capsule Substances 0.000 claims description 25
- 229920001223 polyethylene glycol Polymers 0.000 claims description 12
- -1 polyoxyethylene Polymers 0.000 claims description 12
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 10
- 239000000194 fatty acid Substances 0.000 claims description 10
- 229930195729 fatty acid Natural products 0.000 claims description 10
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 9
- 239000004359 castor oil Substances 0.000 claims description 8
- 235000019438 castor oil Nutrition 0.000 claims description 8
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 8
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 6
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 6
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 239000000049 pigment Substances 0.000 claims description 5
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 3
- 239000007795 chemical reaction product Substances 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 239000004408 titanium dioxide Substances 0.000 claims description 3
- 108010025899 gelatin film Proteins 0.000 claims description 2
- 239000000203 mixture Substances 0.000 description 11
- 239000007788 liquid Substances 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229940092980 adalat Drugs 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 150000002334 glycols Chemical class 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000012738 dissolution medium Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008389 polyethoxylated castor oil Substances 0.000 description 2
- 229940089949 procardia Drugs 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000007711 solidification Methods 0.000 description 2
- 230000008023 solidification Effects 0.000 description 2
- 230000009974 thixotropic effect Effects 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH1787/89A CH679010A5 (OSRAM) | 1989-05-12 | 1989-05-12 | |
| DE3922021A DE3922021A1 (de) | 1989-05-12 | 1989-07-05 | Nifedipin enthaltende hartgelatinekapseln und ihre herstellung |
| JP2117035A JPH02311416A (ja) | 1989-05-12 | 1990-05-08 | ニフェジピン含有硬質ゼラチンカプセル剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH1787/89A CH679010A5 (OSRAM) | 1989-05-12 | 1989-05-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH679010A5 true CH679010A5 (OSRAM) | 1991-12-13 |
Family
ID=4218595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH1787/89A CH679010A5 (OSRAM) | 1989-05-12 | 1989-05-12 |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JPH02311416A (OSRAM) |
| CH (1) | CH679010A5 (OSRAM) |
| DE (1) | DE3922021A1 (OSRAM) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA876263B (en) * | 1986-09-22 | 1989-04-26 | South African Druggists Ltd | Pharmaceutical composition |
-
1989
- 1989-05-12 CH CH1787/89A patent/CH679010A5/de not_active IP Right Cessation
- 1989-07-05 DE DE3922021A patent/DE3922021A1/de not_active Withdrawn
-
1990
- 1990-05-08 JP JP2117035A patent/JPH02311416A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DE3922021A1 (de) | 1990-11-15 |
| JPH02311416A (ja) | 1990-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3438830C2 (OSRAM) | ||
| EP0117888B1 (de) | Flüssigzubereitungen von Dihydropyridinen, ein Verfahren zu ihrer Herstellung, sowie ihre Verwendung bei der Bekämpfung von Erkrankungen | |
| EP1365737B1 (de) | Stabile salze von o-acetylsalicylsäure mit basischen aminosäuren | |
| DE69300913T2 (de) | Polymorph Terazosin und pharmazeutische Zusammenstellung. | |
| DE3042332C2 (OSRAM) | ||
| DE3500103A1 (de) | Pharmazeutische zubereitung mit einem in wasser und verdauungssaeften schwer loeslichen wirkstoff | |
| DE2416736A1 (de) | Neue arzneimittelzubereitungen in form von waessrigen suspensionen | |
| CH640734A5 (de) | Cerebralwirksames mittel. | |
| DE3738236A1 (de) | Beisskapsel | |
| DE1467907C3 (de) | Verfahren zur Herstellung von .Weich gelatinekapseln | |
| CH645805A5 (de) | Suppositorien mit einem gehalt an einer verbindung mit bronchodilatatorischer aktivitaet. | |
| DE2947624A1 (de) | Beta, gamma -dihydropolyprenylalkohol und diesen enthaltendes blutdrucksenkendes arzneimittel | |
| EP0143857A1 (de) | Coronartherapeutikum in Form von Weichgelatine-Kapseln | |
| CH679010A5 (OSRAM) | ||
| AT392904B (de) | Verfahren zur herstellung einer zur oralen verabreichung von etoposid bestimmten weichgelantinekapsel | |
| DE69101220T2 (de) | Öliges ketoprofen enthaltende kapsel. | |
| DE1806926A1 (de) | Lithiumsalz der Hydrochinonsulfonsaeure | |
| EP1021198A1 (de) | Flavonolignan-zubereitungen, insbesondere silymarin-zubereitungen | |
| AT402690B (de) | Sprühbare lösungen mit blutdrucksenkender wirkung und verfahren zu ihrer herstellung sowie ihre verwendung | |
| DE2209526C3 (de) | Coronartherapeutlkum in Form von Gelatine-BeiBkapseln | |
| DE3042975A1 (de) | Mikrodispersion mit einem wirkstoff und/oder einem reagens in salzform als disperser phase | |
| DE3023109A1 (de) | Methoxsalenpraeparat zur oralen verabreichung | |
| DE2523108A1 (de) | Heilmittel gegen sichelzellenanaemie | |
| EP0240874B1 (de) | Hochresorbierbare Zubereitungsform des Hymecromons und Verfahren zur Herstellung derselben | |
| EP0005121B1 (de) | Verfahren zum Stabilisieren von 4-Methyl-5-(2'-chloraethyl)-thiazol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PFA | Name/firm changed |
Owner name: MEPHA AG Free format text: MEPHA AG#DORNACHERSTRASSE 114#4147 AESCH BL (CH) -TRANSFER TO- MEPHA AG#DORNACHERSTRASSE 114#4147 AESCH BL (CH) |
|
| PL | Patent ceased |